01 · Regulatory facts · United States
FDA is asking how these choices should fit together.
On 5 October 2026, FDA announced a request for information on early-phase clinical trials of ibogaine drug products. The notice was published on 6 October. It asks for evidence and views on patient populations, dose selection and escalation, care setting, cardiac and neurological monitoring, stopping rules, informed consent and independent safety oversight.
Status: open request for information, not guidance. FDA says the responses may inform how it considers these elements in future IND reviews. The notice does not predetermine FDA’s action on any submission. Comments are due by 11:59 p.m. Eastern Time for electronic submissions.
02 · Tenvia interpretation
One design choice creates several review questions.
A proposed dose or escalation plan has implications for who may enter the study, where participants are cared for, what must be monitored and when the study should pause. Sponsors and CROs can use this consultation as a discussion example: keep the source passage, the assumptions and the affected protocol sections together so qualified specialists can assess each relationship.
Record the proposed choice, the evidence supporting it and the consultation status of any regulatory reference.
Examine eligibility, monitoring, care setting, stopping rules and oversight together, noting questions that remain unresolved.
Clinical, safety and regulatory specialists judge the evidence and record the rationale for the protocol version under review.
This is a protocol-development discussion, not an announcement that Tenvia performs these checks automatically or supports an ibogaine-specific workflow.
Explore the cross-functional review discussion guide →03 · Important boundaries
Consultation questions are not design instructions.
The FDA request concerns ibogaine drug products in early-phase research. Its proposed approaches cannot be applied automatically to other products or studies. This article does not recommend a dose, population, monitoring schedule or stopping rule. Those decisions require study-specific evidence and qualified human review.
Tenvia does not claim regulatory endorsement, compliance, clinical safety or approval from this consultation.
04 · Official sources
Read FDA’s request in context.
FDA announcement, 5 October 2026 ↗
FDA Federal Register notice, 6 October 2026, Docket FDA-2026-N-10429 ↗
Sources reviewed 7 October 2026. This is independent Tenvia commentary, not an FDA publication or medical or regulatory advice. Recheck the docket for later changes.